A REVIEW OF IMB-808

eighteen How these distinct microbiome modifications decrease the probability of CDI recurrence compared with vancomycin might be assessed in foreseeable future studies as ibezapolstat developments into Period 2/3 scientific tests. Currently, these final results offer crucial insights into microbiome improvements connected with differing mechanisms